High positivity of anti-CCP antibodies in patients with Down syndrome (original) (raw)

Abstract

The aim of the present study was to evaluate the prevalence of anti-cyclic citrullinated peptide (CCP) antibodies in patients with Down’s syndrome (DS) previously tested for IgM rheumatoid factor (RF) and to correlate the results with clinical findings. Eighty-eight patients with DS previously tested for IgM-RF were divided into two groups matched for sex and age. Group A consists of 42 RF positive patients and group B of 44 RF negative patients. The presence of anti-CCP antibody was determined using a second-generation enzyme-linked immunosorbent assay. A total of 52.3% (45/86) of DS patients were positive for anti-CCP antibodies. Twenty-four patients (57.1%) of the RF positive group and 21 (47.7%) of the RF negative group presented anti-CCP circulating antibodies. The concordance between both tests was 54.6%. None of the patients had clinical evidence of rheumatoid arthritis or juvenile idiopathic arthritis. Although a high prevalence of anti-CCP antibodies was observed in DS patients, no association has been found presently with clinical disease. Careful follow-up of these patients will be necessary to clarify the real significance of these findings.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

The alternative text for this image may have been generated using AI.

Similar content being viewed by others

References

  1. National Birth Defects Prevention Network (2003) Birth defects surveillance data from selected states, 1996–2000. Birth Defects Res A Clin Mol Teratol 67:729–818
    Article Google Scholar
  2. Leonard S, Bower C, Petterson B, Leonard H (2000) Survival of infants born with Down’s syndrome 1980–96. Paediatr Perinat Epidemiol 14:163–171
    Article CAS PubMed Google Scholar
  3. Pueschel SM, Anneren G, Durlach R et al (1995) Guidelines for optimal care of persons with Down syndrome. Acta Paediatr 84:823–827
    Article CAS PubMed Google Scholar
  4. Ugazio AG, Maccario R, Notarangelo LD, Burgio GR (1990) Immunology of Down syndrome: a review. Am J Med Genet 7:202–212
    Google Scholar
  5. Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2005) Celiac disease in children and adolescents with Down syndrome. J Pediatr 81(5):373–376
    Article Google Scholar
  6. Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2006) Alterations of TSH in Down syndrome patients: a hard interpretation. Rev Med Lab 46:333–337
    Google Scholar
  7. Anwar AJ, Walker JD, Frier BM (1998) Type-1 diabetes mellitus and Down’s syndrome: prevalence, management and diabetic complications. Diabet Med 15:160–163
    Article CAS PubMed Google Scholar
  8. Goldacre MJ, Wotton CJ, Seagroatt V, Yeats D (2004) Cancers and immune related diseases associated with Down’s syndrome: a record linkage study. Arch Dis Child 89:1014–1017
    Article CAS PubMed PubMed Central Google Scholar
  9. Padmakumar B, Evans Jones LG, Sills JA (2002) Is arthritis more common in children with Down syndrome? Rheumatology 41:1191–1193
    Article CAS PubMed Google Scholar
  10. Yancey C, Zmijewski C, Athreya BH, Doughty RA (1984) Arthropathy of Downs’ syndrome. Arthritis Rheum 27:929–934
    Article CAS PubMed Google Scholar
  11. Olson JC, Bender JC, Levinson JE, Oestreich A, Loveli D (1990) Arthropathy of Down syndrome. Pediatrics 86:931–936
    CAS PubMed Google Scholar
  12. Kinnel HG (1984) Arthritis in Down’s syndrome. Br J Radiol 54:1167
    Google Scholar
  13. Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680
    Article CAS PubMed Google Scholar
  14. Grahane R (1998) Hypermobility syndrome. In: Kilpell JH, Fieppe PA (eds) Rheumatology, 2nd edn. Mosby, London, S8–51.1–51.6
  15. Cuadrado E, Barrena MJ (1996) Immune dysfunction in Down’s syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol 78:209–214
    Article CAS PubMed Google Scholar
  16. Jansen AL, van den Horst-Bruisma IE, van Shaardenburg D, Van den Stad RJ, de Konig MH, Dijkmans BA (2002) Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 29:2074–2076
    PubMed Google Scholar
  17. Hingh YC, Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, Vries E (2005) Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr 147:744–747
    Article PubMed Google Scholar
  18. Franciotta D, Verri A, Zardini E, Andreoni L, Amici M, Moratti R, Nespoli L (2006) Interferon γ and interleukin-4 producing T cells in Down’s syndrome. Neurosci Lett 395:67–70
    Article CAS PubMed Google Scholar
  19. Berglin E, Padyukov L, Sundin U et al (2004) A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6:303–308
    Article Google Scholar
  20. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ (2005) Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 47(3):171–176
    Article PubMed Google Scholar
  21. Ferraro AS, Newkirk MM (1993) Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis. Clin Exp Immunol 92:425–431
    Article CAS PubMed PubMed Central Google Scholar
  22. Newkirk MM (2002) Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 104:1–13
    Article CAS PubMed Google Scholar
  23. Posnett DN, Edinger J (1997) When do microbes stimulate rheumatoid factor? J Exp Med 185:1721–1723
    Article CAS PubMed PubMed Central Google Scholar
  24. Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P (2006) Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 33:647–651
    CAS PubMed Google Scholar
  25. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P (2006) Deiminated Epstein–Barr virus nuclear antigen 1 is a target of anti citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 54:733–741
    Article CAS PubMed Google Scholar
  26. Ates A, Karaaslan Y, Aksaray S (2007) Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 26(4):499–504 (May 3)
    Article PubMed Google Scholar
  27. Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26(2):201–204 (Mar 30)
    Article PubMed Google Scholar

Download references

Acknowledgment

This work was supported by a grant from the Araucária Foundation—Paraná. IJMR is a recipient of the Brazilian National Research Council CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) Research Fellowship (200936/2004-2).

Author information

Authors and Affiliations

  1. Laboratory of Immunopathology, Department of Clinical Pathology, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil
    Renato M. Nisihara, Iara T. Messias-Reason & Shirley R. R. Utiyama
  2. Rheumatology Clinic, Evangelic University Hospital of Curitiba, Curitiba, Brazil
    Thelma L. Skare & Marília B. G. Silva
  3. Down syndrome Clinic, Clinical Hospital, Federal University of Paraná, Curitiba, Brazil
    Nanci P. Oliveira & Patricia T. Fiedler
  4. Ave. Arthur da Silva Bernardes, 753, Curitiba, Paraná, Brazil, 80 320 300
    Renato M. Nisihara

Authors

  1. Renato M. Nisihara
  2. Thelma L. Skare
  3. Marília B. G. Silva
  4. Iara T. Messias-Reason
  5. Nanci P. Oliveira
  6. Patricia T. Fiedler
  7. Shirley R. R. Utiyama

Corresponding author

Correspondence toRenato M. Nisihara.

Rights and permissions

About this article

Cite this article

Nisihara, R.M., Skare, T.L., Silva, M.B.G. et al. High positivity of anti-CCP antibodies in patients with Down syndrome.Clin Rheumatol 26, 2031–2035 (2007). https://doi.org/10.1007/s10067-007-0606-1

Download citation

Keywords